developed mucoadhesive carriers based on food-grade polymers such as chitosan, alginate and pectin for the delivery of drugs to the colon [9]. Due to their ability to overcome gastric fluid and mucoadhesive properties, these systems are able to adhere to mucus and facilitate the effective absorption of poorly soluble substances delivered. Moreover, modulation of the release of chemotherapeutic agents has made it possible to reduce or eliminate their side effects. Thus, they present great potential for the development of next-generation personalized medicine platforms. However, the absence of an ex vivo experimental model to be able to carry out more in-depth studies (physicochemical interactions, toxicological aspects, etc.) of the potential of these systems and the gap between academic research and clinical application are the main obstacles to their development [9]. Bakshi et al. focused on exploiting the metabolism of the gut microbiome for targeted colon drug delivery. The different delivery systems and modulation of the microbiota are highlighted. The potential of using bacteria for the production of therapeutic molecules is also discussed. In particular, the manipulation of gut bacteria to express specific enzymes that activate drugs for the treatment of certain types of cancer. However, there are few in vitro, in vivo and clinical studies to evaluate the current experimental evidence. Therefore, an increase in such studies and research aimed at determining the consequences of microbial metabolism of these drugs (in relation to their efficacy and toxicity) in various pathological conditions of the colon is of enormous interest [10]. Finally, Ibrahim reviewed the advances in polysaccharide-based oral colon delivery systems, highlighting the possibility of creating delivery platforms that are unaffected by the gastric environment and are selectively digested by colon bacterial enzymes. Unfortunately, during disease states, a dilution and/or change in the bacterial population occurs, which is the main challenge of this administration approach. Co-administration of probiotics could compensate for the bacterial loss. However, this research is limited to the preclinical level and further studies are needed for industrial scalability and clinical use of these technologies [11]. This review focuses on technological and biological characterization studies of the most recent total food systems proposed for colon-targeted delivery. The main characteristic of these systems is the nature of their components: all their components are considered food or food additives approved for human use. The review is the result of an extensive screening process of numerous articles identified on PubMed, Google Scholar, SciELO and ScienceDirect platforms, setting the last 5 years as the timeframe and using as keywords: colon targeting, food polymers in colon-targeting, resveratrol, quercetin and other nutraceuticalids, IBD, ulcerative colitis, Crohn's disease, colorectal cancer, and other colon disorders. The objective screening phase made it possible to significantly reduce sources, identifying only those studies that fell within the previously provided definition of total food-grade colon-targeting systems, preferring, where possible, studies based on eco-friendly production processes.